Pulmonary Fibrosis

Respiratory
7
Pipeline Programs
4
Companies
12
Clinical Trials
1 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
3
0
1
2
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
4100%
+ 8 programs with unclassified modality

On Market (1)

Approved therapies currently available

Boehringer Ingelheim
OFEVApproved
nintedanib
Boehringer Ingelheim
oral2014

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
9 programs
3
1
NintedanibPhase 4Small Molecule1 trial
BIBF 1120Phase 21 trial
NintedanibPhase 2Small Molecule1 trial
low dose BIBF1120 once dailyPhase 21 trial
Multiple-Breath-WashoutN/A1 trial
+4 more programs
Active Trials
NCT06179342Completed90Est. Mar 2024
NCT06162884Recruiting200Est. Aug 2028
NCT06912659Active Not Recruiting157Est. Dec 2026
+6 more trials
Pulse Biosciences
Pulse BiosciencesCA - Hayward
1 program
1
INOpulse®Phase 31 trial
Active Trials
NCT03267108TerminatedEst. Jun 2023
Lassen Therapeutics
Lassen TherapeuticsCA - San Diego
1 program
1
LASN01Phase 1/21 trial
Active Trials
NCT05331300CompletedEst. Nov 2024
Vicore Pharma
Vicore PharmaSweden - Stockholm
1 program
Digital cognitive behavioral therapyN/A1 trial
Active Trials
NCT05330312Completed119Est. Nov 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Boehringer IngelheimNintedanib
Pulse BiosciencesINOpulse®
Boehringer IngelheimNintedanib
Boehringer IngelheimBIBF 1120
Boehringer Ingelheimlow dose BIBF1120 once daily
Lassen TherapeuticsLASN01
Boehringer IngelheimThe BALANCE Study: A Study in Spain to Find Out Whether a Patient Support Program Helps People With
Boehringer IngelheimSingle Time Point Prediction as Earlier Diagnosis of Progressive Pulmonary Fibrosis
Boehringer Ingelheimnintedanib
Vicore PharmaDigital cognitive behavioral therapy
Boehringer IngelheimMultiple-Breath-Washout
Boehringer Ingelheimnintedanib

Clinical Trials (12)

Total enrollment: 1,438 patients across 12 trials

NCT04619680Boehringer IngelheimNintedanib

The Study of the Use of Nintedanib in Slowing Lung Disease in Patients With Fibrotic or Non-Fibrotic Interstitial Lung Disease Related to COVID-19

Start: Nov 2020Est. completion: Mar 2024121 patients
Phase 4Completed
NCT03267108Pulse BiosciencesINOpulse®

A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis at Risk for Pulmonary Hypertension

Start: Dec 2020Est. completion: Jun 2023
Phase 3Terminated
NCT01417156Boehringer IngelheimNintedanib

Safety and PK Study of BIBF 1120 in Japanese Patients With IPF: Follow up Study From 1199.31(NCT01136174)

Start: Sep 2011Est. completion: Oct 201520 patients
Phase 2Completed
NCT01170065Boehringer IngelheimBIBF 1120

Roll Over Study From 1199.30 BIBF 1120 in Idiopathic Pulmonary Fibrosis (IPF)

Start: Jun 2010Est. completion: Sep 2016198 patients
Phase 2Completed
NCT00514683Boehringer Ingelheimlow dose BIBF1120 once daily

Safety And Efficacy of BIBF 1120 in Idiopathic Pulmonary Fibrosis

Start: Aug 2007432 patients
Phase 2Completed
NCT05331300Lassen TherapeuticsLASN01

A Study to Evaluate the Safety, Preliminary Efficacy, and Pharmacokinetic Properties of LASN01 in Healthy Subjects and in Patients With Pulmonary Fibrosis or Thyroid Eye Disease

Start: Jun 2022Est. completion: Nov 2024
Phase 1/2Completed
NCT06912659Boehringer IngelheimThe BALANCE Study: A Study in Spain to Find Out Whether a Patient Support Program Helps People With

The BALANCE Study: A Study in Spain to Find Out Whether a Patient Support Program Helps People With Pulmonary Fibrosis Who Take Nintedanib

Start: Jun 2025Est. completion: Dec 2026157 patients
N/AActive Not Recruiting
NCT06162884Boehringer IngelheimSingle Time Point Prediction as Earlier Diagnosis of Progressive Pulmonary Fibrosis

Single Time Point Prediction as Earlier Diagnosis of Progressive Pulmonary Fibrosis

Start: Nov 2024Est. completion: Aug 2028200 patients
N/ARecruiting
NCT05676112Boehringer Ingelheimnintedanib

Safety of Nintedanib in Real World in China

Start: Dec 2023Est. completion: Sep 20260
N/AWithdrawn
NCT05330312Vicore PharmaDigital cognitive behavioral therapy

Controlled Investigation to Evaluate Impact of dCBT on Psychological Symptom Burden in Adult Subjects With PF

Start: Apr 2022Est. completion: Nov 2023119 patients
N/ACompleted
NCT06179342Boehringer IngelheimMultiple-Breath-Washout

Multiple Breath Washout as a Method for Diagnosing Lung Diseases

Start: Jun 2021Est. completion: Mar 202490 patients
N/ACompleted
NCT03242759Boehringer Ingelheimnintedanib

Non-Interventional Study (NIS) Collecting Experiences For IPF in Taiwan

Start: Aug 2017Est. completion: Feb 2020101 patients
N/ACompleted

Related Jobs in Respiratory

Ausbildung zum Pharmakanten (m/w/d)

Ferring Pharmaceuticals
Kiel, Germany
20h ago

Global Senior Medical Director – Respiratory Pipeline Medical Lead

Pfizer
United States - New York - New York City
Yesterday
$275K - $458K/yr

Praktikant (m/w/d) Marketing Onkologie

Amgen
Germany - Munich
Yesterday

Sr Product Manager, Monarch (1 of 2)

Johnson & Johnson
Santa Clara, California, United States of America
Yesterday
$142K - $245K/yr

Laboratory Assistant (m/w/d)

Ferring Pharmaceuticals
Kiel, Germany
Yesterday

Director Quality Control (m/w/d)

Ferring Pharmaceuticals
Kiel, Germany
Yesterday

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 1,438 patients
4 companies competing in this space

Related Indications

Asthma(378)Pulmonary Disease, Chronic Obstructive(263)Chronic Obstructive Pulmonary Disease(123)Idiopathic Pulmonary Fibrosis(90)COPD(74)Chronic Obstructive Pulmonary Disease (COPD)(38)Pulmonary Embolism(27)Respiratory Syncytial Virus Infections(26)Severe Asthma(21)Lung Diseases, Interstitial(19)